GO:0004757 sepiapterin reductase (NADP+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004757 describes sepiapterin reductase (NADP+) activity, an oxidoreductase that catalyzes the NADP+-dependent interconversion of 7,8-dihydrobiopterin and sepiapterin, and the NADP+-dependent conversion of (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin to 6-pyruvoyl-5,6,7,8-tetrahydropterin.
• Sepiapterin reductase (SPR) is a key enzyme in tetrahydrobiopterin (BH4) biosynthesis, and its activity is required for the terminal steps of the BH4 pathway.
• SPR exhibits broad substrate tolerance, including NADPH-dependent dicarbonyl reductase activity toward non-pteridine alpha-diketo compounds.
• The enzyme uses NADP+/NADPH as a cofactor, and coenzyme binding can stimulate isomerase activity during tetrahydrobiopterin biosynthesis.
• Structurally, SPR is a short-chain dehydrogenase/reductase with a conserved catalytic triad; residues such as Tyr171 and Ser158 are functionally important.
• Dysregulation of SPR and BH4 metabolism has been linked to neurological and metabolic phenotypes, making SPR a target for CRISPR-based disease modeling.
Description
Sepiapterin reductase (NADP+) activity (GO:0004757) is a molecular function defined by the oxidoreductase reactions that interconvert pterin derivatives using NADP+ as an electron acceptor. Specifically, the term covers the reversible conversion of 7,8-dihydrobiopterin and sepiapterin, as well as the NADP+-dependent conversion of (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin to 6-pyruvoyl-5,6,7,8-tetrahydropterin. This activity is essential for the biosynthesis of tetrahydrobiopterin (BH4), a critical cofactor for aromatic amino acid hydroxylases and nitric oxide synthases. Researchers study GO:0004757 to understand BH4-related metabolic and neurological disorders, and to dissect the catalytic mechanism of sepiapterin reductase (SPR). The enzyme has been purified and characterized from rat erythrocytes, where it also displays carbonyl reductase activity. Its ability to act on non-pteridine dicarbonyl compounds further highlights its broad substrate specificity.
sepiapterin reductase (NADP+) activity At A Glance
| GO ID | GO:0004757 |
|---|---|
| GO term | sepiapterin reductase (NADP+) activity |
| Ontology | molecular_function |
| Synonym | 7,8-dihydrobiopterin:NADP+ oxidoreductase activity |
| Major function | Catalyzes NADP+-dependent oxidoreduction of pterins in tetrahydrobiopterin biosynthesis |
| Cofactor | NADP+/NADPH |
| EC number | 1.1.1.153 (sepiapterin reductase) |
| Substrates | 7,8-dihydrobiopterin, sepiapterin, (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin |
| Products | Sepiapterin, 6-pyruvoyl-5,6,7,8-tetrahydropterin, NADPH |
What Is GO:0004757?
In simple terms, GO:0004757 describes the enzymatic activity of sepiapterin reductase (SPR) that uses NADP+ to oxidize pterin substrates. The official definition includes two reactions: (1) 7,8-dihydrobiopterin + NADP+ = sepiapterin + NADPH + H+, and (2) (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin + 2 NADP+ = 6-pyruvoyl-5,6,7,8-tetrahydropterin + 2 H+ + 2 NADPH. This activity is synonymous with 7,8-dihydrobiopterin:NADP+ oxidoreductase activity. It is a molecular_function term in the Gene Ontology and is central to tetrahydrobiopterin biosynthesis.
Why Is sepiapterin reductase (NADP+) activity Important in Cell Biology?
GO:0004757 is important because sepiapterin reductase (SPR) catalyzes the final steps of tetrahydrobiopterin (BH4) biosynthesis, and BH4 is an essential cofactor for phenylalanine, tyrosine, and tryptophan hydroxylases as well as nitric oxide synthases. Perturbations in SPR activity can alter BH4 levels, impacting neurotransmitter synthesis and cardiovascular function. The enzyme's broad substrate range, including dicarbonyl reductase activity, suggests additional metabolic roles beyond pterin metabolism. Understanding GO:0004757 at the molecular level informs research on neurological and metabolic disorders and supports the development of targeted CRISPR models.
• SPR is required for the terminal steps of BH4 biosynthesis, a cofactor for aromatic amino acid hydroxylases.
• BH4 deficiency is associated with neurological disorders such as dopa-responsive dystonia and hyperphenylalaninemia.
• SPR exhibits NADPH-dependent dicarbonyl reductase activity, linking it to broader carbonyl metabolism.
• The enzyme can act on non-pteridine alpha-diketo compounds, indicating substrate promiscuity.
• Coenzyme binding stimulates isomerase activity, revealing regulatory complexity in BH4 biosynthesis.
• Key catalytic residues Tyr171 and Ser158 are functionally important, providing targets for mutagenesis studies.
• The crystal structure of SPR at 1.25 A resolution reveals its binding mode to pterins and brain neurotransmitters.
• SPR has been purified and characterized from rat erythrocytes, offering a model for enzyme kinetics.
• cDNA cloning and expression of rat liver SPR enables recombinant studies and functional assays.
• GO:0004757 is a molecular_function term that can be used in enrichment analyses of BH4-related pathways.
Molecular Mechanism of sepiapterin reductase (NADP+) activity
Substrate Binding and Catalysis
In simple terms: SPR grabs pterin molecules and uses NADP+ to modify them.
Sepiapterin reductase binds pterin substrates such as 7,8-dihydrobiopterin and sepiapterin in a pocket that accommodates the pterin ring and the NADP+ cofactor. The catalytic mechanism involves hydride transfer between the substrate and NADP+, facilitated by a conserved catalytic triad. Mutagenesis studies identified Tyr171 and Ser158 as functionally important residues for catalysis. The enzyme also catalyzes the NADP+-dependent conversion of (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin to 6-pyruvoyl-5,6,7,8-tetrahydropterin, a key step in BH4 biosynthesis.
Cofactor Requirements and Isomerase Activity
In simple terms: NADPH helps SPR do more than one type of chemical reaction.
SPR requires NADP+ or NADPH for its oxidoreductase activity. Beyond its canonical reaction, the enzyme exhibits NADPH-dependent dicarbonyl reductase activity toward non-pteridine alpha-diketo compounds. Coenzyme stimulation of isomerase activity has been observed, suggesting that NADPH binding can modulate additional catalytic functions during tetrahydrobiopterin biosynthesis. This dual reactivity underscores the enzyme's versatility in pterin and carbonyl metabolism.
Structural Features and Binding Mode
In simple terms: The 3D structure of SPR shows how it holds pterins and neurotransmitters.
The 1.25 A crystal structure of sepiapterin reductase revealed its binding mode to pterins and brain neurotransmitters, providing a structural basis for substrate specificity. SPR belongs to the short-chain dehydrogenase/reductase family, with a Rossmann-fold NADP+-binding domain. The active site accommodates both pterin substrates and non-pteridine dicarbonyl compounds, consistent with its broad substrate tolerance. Key residues such as Tyr171 and Ser158 line the active site and are critical for catalysis.
Enzymatic Assays and Kinetic Characterization
In simple terms: Scientists measure SPR activity by tracking how fast it converts substrates.
SPR activity is typically assayed by monitoring NADPH production or consumption spectrophotometrically. Purification from rat erythrocytes enabled early kinetic characterization, including determination of Km values for pterin substrates. The enzyme was also shown to catalyze carbonyl reduction of various compounds, which can be measured using standard reductase assays. Recombinant SPR expressed from cloned cDNA facilitates detailed kinetic and inhibition studies.
Key Genes Involved in GO:0004757 sepiapterin reductase (NADP+) activity
The following genes and proteins are directly or functionally associated with sepiapterin reductase (NADP+) activity and tetrahydrobiopterin metabolism.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SPR | Sepiapterin reductase; catalyzes NADP+-dependent pterin oxidoreduction | Core enzyme for GO:0004757; target for knockout and point mutation studies |
| GCH1 | GTP cyclohydrolase 1; rate-limiting enzyme in BH4 biosynthesis | Upstream of SPR; co-target for pathway analysis |
| PTS | 6-pyruvoyltetrahydropterin synthase; converts 6-pyruvoyl-tetrahydropterin to BH4 | Downstream of SPR; relevant for BH4 pathway modeling |
| QDPR | Dihydropteridine reductase; regenerates BH4 | Recycling enzyme; interacts with SPR pathway |
| PAH | Phenylalanine hydroxylase; uses BH4 as cofactor | Disease relevance in hyperphenylalaninemia |
| TH | Tyrosine hydroxylase; uses BH4 for dopamine synthesis | Neurological relevance; BH4-dependent |
| TPH1 | Tryptophan hydroxylase 1; uses BH4 for serotonin synthesis | Neurological relevance; BH4-dependent |
| TPH2 | Tryptophan hydroxylase 2; neuronal serotonin synthesis | Neurological relevance; BH4-dependent |
| NOS1 | Neuronal nitric oxide synthase; requires BH4 | Cardiovascular and neuronal signaling |
| NOS2 | Inducible nitric oxide synthase; requires BH4 | Inflammation and immune response |
| NOS3 | Endothelial nitric oxide synthase; requires BH4 | Vascular function; BH4-dependent |
| DHFR | Dihydrofolate reductase; can regenerate BH4 | Alternative BH4 recycling pathway |
| PCBD1 | Pterin-4 alpha-carbinolamine dehydratase; in BH4 regeneration | BH4 homeostasis |
| GCHFR | GTP cyclohydrolase I feedback regulator | Regulates BH4 biosynthesis |
| ALDH2 | Aldehyde dehydrogenase; may interact with carbonyl metabolism | Potential cross-talk with SPR dicarbonyl activity |
| CBR1 | Carbonyl reductase 1; similar dicarbonyl reductase activity | Comparative studies with SPR |
| AKR1B1 | Aldo-keto reductase; broad carbonyl reduction | Substrate overlap with SPR |
| SPR (isoforms) | Splice variants or post-translational modifications | Isoform-specific functions |
How Is sepiapterin reductase (NADP+) activity Regulated?
Sepiapterin reductase (NADP+) activity is regulated at multiple levels. Coenzyme availability (NADP+/NADPH ratio) directly influences catalytic rate and isomerase activity. The enzyme's expression can be modulated by transcriptional and post-transcriptional mechanisms, as suggested by cDNA cloning and expression studies. Additionally, feedback regulation of the BH4 pathway by GCH1 and GCHFR may indirectly affect SPR activity. Structural studies indicate that substrate binding and active-site residues control catalytic efficiency.
sepiapterin reductase (NADP+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SPR | Sepiapterin reductase deficiency; dopa-responsive dystonia | SPR knockout cell line; point mutation knock-in |
| GCH1 | GTP cyclohydrolase 1 deficiency; hyperphenylalaninemia | GCH1 knockout; BH4 pathway analysis |
| PAH | Phenylketonuria; hyperphenylalaninemia | PAH mutant knock-in; BH4 cofactor studies |
| NOS3 | Endothelial dysfunction; cardiovascular disease | NOS3 knockout; BH4 supplementation |
| TH | Dopamine-related neurological disorders | TH knockout; BH4-dependent dopamine synthesis |
Neurological Disorders and BH4 Deficiency
Sepiapterin reductase deficiency is a rare inherited disorder of BH4 metabolism that can cause dopa-responsive dystonia, developmental delay, and neurotransmitter deficiencies. Because SPR catalyzes the final steps of BH4 biosynthesis, reduced GO:0004757 activity leads to decreased BH4 levels, impairing tyrosine and tryptophan hydroxylases. Animal models and patient-derived cells are used to study the molecular consequences of SPR mutations.
Hyperphenylalaninemia and Metabolic Phenotypes
BH4 is a required cofactor for phenylalanine hydroxylase (PAH), and defects in BH4 biosynthesis can cause hyperphenylalaninemia. SPR dysfunction may contribute to altered phenylalanine metabolism, although the clinical spectrum varies. Research using recombinant SPR and mutant variants helps dissect the impact of specific residues on enzyme activity.
Cardiovascular and Nitric Oxide Signaling
BH4 is essential for nitric oxide synthase (NOS) activity, and BH4 deficiency can lead to endothelial dysfunction and cardiovascular disease. SPR activity influences BH4 availability, thereby affecting NO production. Studies on SPR knockout or knockdown models can reveal consequences for vascular function.
From sepiapterin reductase (NADP+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SPR loss alter BH4 levels? | SPR knockout cell line (e.g., HEK293 or iPSC-derived neurons) |
| Which residues are essential for catalysis? | Point mutation knock-in of Tyr171 or Ser158 |
| Can wild-type SPR rescue BH4 deficiency? | Knock-in of tagged SPR for expression and localization |
| Does SPR overexpression affect neurotransmitter synthesis? | Overexpression of SPR in neuronal cell lines |
| What is the impact of SPR on nitric oxide signaling? | SPR knockout endothelial cells; NO measurement |
| Can CRISPR screening identify modifiers of BH4 pathway? | Genome-wide CRISPR library screening in BH4-dependent cells |
How to Study the sepiapterin reductase (NADP+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Spectrophotometric assay | NADPH production/consumption | Kinetic characterization of SPR |
| HPLC with fluorescence detection | Pterin levels (BH4, sepiapterin) | Metabolic profiling |
| X-ray crystallography | 3D structure of SPR-ligand complexes | Mechanistic studies |
| Site-directed mutagenesis | Effect of point mutations on activity | Catalytic residue identification |
| CRISPR knockout | Loss-of-function phenotype | BH4 pathway analysis |
| Western blot | SPR protein expression | Validation of knockout/overexpression |
| qRT-PCR | SPR mRNA levels | Transcriptional regulation |
| Mass spectrometry | BH4 and metabolite quantification | Metabolomics |
Enzymatic Activity Assays
Sepiapterin reductase activity can be measured spectrophotometrically by monitoring NADPH production or consumption at 340 nm using pterin substrates. Dicarbonyl reductase activity is assayed with alpha-diketo compounds. These methods are essential for characterizing wild-type and mutant SPR variants.
Structural Biology and Crystallography
X-ray crystallography of SPR at 1.25 A resolution revealed the binding mode to pterins and neurotransmitters. Structural studies combined with site-directed mutagenesis identify key catalytic residues and guide inhibitor design.
Gene Expression and Knockout Studies
CRISPR-Cas9 knockout of SPR in cell lines enables loss-of-function studies to assess BH4 levels and downstream effects. Overexpression of SPR cDNA can rescue phenotypes and confirm specificity.
Metabolomics and BH4 Quantification
Mass spectrometry-based metabolomics can quantify BH4 and related pterins in cells and tissues. These methods are used to evaluate the impact of SPR mutations on the BH4 pathway.
How CRISPR Can Be Used to Study GO:0004757 sepiapterin reductase (NADP+) activity
Knockout
CRISPR-Cas9 knockout of SPR generates cell lines with complete loss of sepiapterin reductase (NADP+) activity, enabling studies on BH4 depletion and downstream metabolic consequences. These models are useful for validating the role of GO:0004757 in neurotransmitter synthesis and cellular stress responses.
Point Mutation
Point mutation knock-in of catalytic residues such as Tyr171 or Ser158 allows precise dissection of their roles in catalysis and substrate binding. CRISPR-mediated homology-directed repair can introduce these mutations into the endogenous SPR locus, preserving physiological expression levels.
Knock-in
Knock-in of tagged SPR (e.g., FLAG or GFP) enables visualization and immunoprecipitation of the enzyme in its native context. This approach helps study protein localization, interactions, and dynamics without overexpression artifacts.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of SPR can elevate enzyme levels to study gain-of-function effects on BH4 biosynthesis and neurotransmitter production. Overexpression models are valuable for rescue experiments and for testing pharmacological modulators.
How EDITGENE Supports sepiapterin reductase (NADP+) activity Research
Researchers studying sepiapterin reductase (NADP+) activity-related genes often need to determine whether a candidate gene is causally involved in BH4 metabolism, neurological function, or disease phenotypes. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation of GO:0004757 and its associated pathways.
Contact EDITGENE today to design your custom CRISPR model for sepiapterin reductase (NADP+) activity research.
Frequently Asked Questions About sepiapterin reductase (NADP+) activity
What is sepiapterin reductase (NADP+) activity?
It is an enzymatic activity defined by GO:0004757 that catalyzes NADP+-dependent oxidoreduction of pterins, including the conversion of 7,8-dihydrobiopterin to sepiapterin and tetrahydrobiopterin to 6-pyruvoyl-tetrahydropterin.
What genes are involved in sepiapterin reductase (NADP+) activity?
The primary gene is SPR, which encodes sepiapterin reductase. Other BH4 pathway genes include GCH1, PTS, QDPR, and PAH.
What is the role of SPR in BH4 biosynthesis?
SPR catalyzes the terminal steps of tetrahydrobiopterin (BH4) biosynthesis, and its activity is essential for producing BH4, a cofactor for aromatic amino acid hydroxylases.
What diseases are associated with sepiapterin reductase deficiency?
SPR deficiency can cause dopa-responsive dystonia, developmental delay, and neurotransmitter deficiencies due to impaired BH4 synthesis.
How is sepiapterin reductase activity measured?
It is typically measured spectrophotometrically by monitoring NADPH production or consumption using pterin substrates.
What is the structure of sepiapterin reductase?
The 1.25 A crystal structure revealed a short-chain dehydrogenase/reductase fold with a Rossmann-fold NADP+-binding domain and key catalytic residues Tyr171 and Ser158.
Can sepiapterin reductase act on non-pteridine substrates?
Yes, SPR exhibits NADPH-dependent dicarbonyl reductase activity toward alpha-diketo compounds of non-pteridine derivatives.
What are the cofactors for sepiapterin reductase?
NADP+ and NADPH are the required cofactors for sepiapterin reductase activity.
How can CRISPR be used to study sepiapterin reductase?
CRISPR knockout, point mutation knock-in, and overexpression models enable functional studies of SPR and its role in BH4 metabolism.
What is the GO ID for sepiapterin reductase (NADP+) activity?
The Gene Ontology ID is GO:0004757, a molecular_function term.
Conclusion
Sepiapterin reductase (NADP+) activity (GO:0004757) is a critical molecular function in tetrahydrobiopterin biosynthesis, with broad implications for neurological, metabolic, and cardiovascular health. The enzyme's catalytic mechanism, structural features, and substrate promiscuity have been well characterized through biochemical and crystallographic studies. CRISPR-based models offer powerful tools to dissect the role of SPR in disease and to identify therapeutic targets. Continued research on GO:0004757 will advance our understanding of BH4-related disorders and potential interventions.
References
- 1. Sueoka T et al.. 1985. Carbonyl reductase activity of sepiapterin reductase from rat erythrocytes.. Biochim Biophys Acta 843(3):193-8 PMID: 3904835
- 2. Katoh S et al.. 1984. Sepiapterin reductase exhibits a NADPH-dependent dicarbonyl reductase activity.. Biochem Biophys Res Commun 118(3):859-66 PMID: 6200109
- 3. Katoh S et al.. 1988. Coenzyme stimulation of isomerase activity of sepiapterin reductase in the biosynthesis of tetrahydrobiopterin.. J Biochem 103(2):286-9 PMID: 3286629
- 4. Sueoka T et al.. 1984. [A new activity of sepiapterin reductase: catalysis of alpha-diketo compounds of non-pteridine derivatives].. Josai Shika Daigaku Kiyo 13(3):508-13 PMID: 6398714
- 5. Sueoka T et al.. 1982. Purification and characterization of sepiapterin reductase from rat erythrocytes.. Biochim Biophys Acta 717(2):265-71 PMID: 7052139
- 6. Fujimoto K et al.. 1999. Functionally important residues tyrosine-171 and serine-158 in sepiapterin reductase.. Biochim Biophys Acta 1431(2):306-14 PMID: 10350607
- 7. Auerbach G et al.. 1997. The 1.25 A crystal structure of sepiapterin reductase reveals its binding mode to pterins and brain neurotransmitters.. EMBO J 16(24):7219-30 PMID: 9405351
- 8. Citron BA et al.. 1990. Isolation and expression of rat liver sepiapterin reductase cDNA.. Proc Natl Acad Sci U S A 87(16):6436-40 PMID: 2201030
